BAY 3620122

BAY 3620122 is a small molecule inhibitor of **soluble guanylate cyclase (sGC)** being developed by **Bayer AG**. It is primarily investigated for the treatment of **vasodilatory shock**, a life-threatening condition characterized by severe hypotension due to excessive systemic vasodilation, often occurring in the context of sepsis or post-cardiac surgery. In these states, an overproduction of nitric oxide (NO) leads to the hyperactivation of sGC and subsequent elevation of cyclic guanosine monophosphate (cGMP), which causes profound smooth muscle relaxation. By inhibiting sGC, BAY 3620122 aims to reduce cGMP levels, thereby restoring vascular responsiveness to vasopressors and stabilizing hemodynamics. The drug is administered via **intravenous infusion** and is currently in early-stage clinical development.